Search the Newsreel

Immunocore's Q2 Earnings Miss Estimates, Kimmtrak Aids Y/Y Revenues

Immunocore (IMCR) reported a Q2 2026 loss of 2 cents per share, wider than analyst estimates, despite revenues of $115.9 million, which beat expectations and increased 18.3% year-over-year. The revenue growth was primarily driven by strong sales of its drug Kimmtrak in the U.S. …

Immunome CBO Kinney Horn sells $2.27m in company stock

Immunome's Chief Business Officer, Kinney Horn, sold 90,616 shares of company stock for $2.27 million after exercising employee stock options. This transaction occurred when the stock was near its 52-week high and followed a 162% gain over the past year. InvestingPro analysis suggests the …

Renaissance Technologies LLC Invests $4.78 Million in Immunovant, Inc. $IMVT

Renaissance Technologies LLC has acquired a new stake of $4.78 million in Immunovant, Inc. (NASDAQ:IMVT), while institutional investors collectively own 47.08% of the company's stock. Despite analysts maintaining a "Moderate Buy" rating with an average target price of $44, Immunovant insiders have sold approximately …

Wall Street Analysts See a 77.91% Upside in Immunocore (IMCR): Can the Stock Really Move This High?

Shares of Immunocore Holdings PLC Sponsored ADR (IMCR) have gained 4.3% over the past four weeks to close the last trading session at $34.5, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts …

Immunocore Holdings plc 2026: Revenue $115.93M, EPS ($0.02) — 10-Q Summary

Immunocore Holdings plc (IMCR) reported strong financial results for the quarter ended 2026, with revenue increasing to $115.93M from $97.96M year-over-year. The company significantly reduced its net loss to $808K (EPS ($0.02)) compared to a $10.3M loss (EPS ($0.2)) in the prior-year quarter. This …

Estrella Immunopharma Inc (ESLA) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Estrella Immunopharma Inc (ESLA), detailing its current stock performance, market capitalization, and analyst ratings. It indicates a "Strong Buy" rating with a significant upside potential based on an updated analyst target price. The article also includes historical …

Évaluations, estimations et prévisions d’analystes pour OSE Immunotherapeutics SA (6OP.HM)

AC Immune earnings missed by CHF0.18, revenue fell short of estimates

How Strong H1 Profits and Kimtrak Survival Data At Immunocore (IMCR) Have Changed Its Investment Story

Immunocore Holdings plc has reported past second-quarter 2026 results showing revenue of US$115.93 million, with net loss narrowing to US$0.808 million, while first-half 2026 revenue reached US$222.60 million and shifted from a prior-period loss to net income of US$12.16 million. Alongside these figures, management …

ImmunityBio (IBRX) Stock Looks Rich On Sales But Strong On Returns

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. ImmunityBio stock has delivered a very strong 321.9% return over the past three years, yet current valuation checks and recent price weakness raise …

The Bull Case For ImmunityBio (IBRX) Could Change Following ANKTIVA’s Broad UAE Approval And Ongoing Losses

In the past week, ImmunityBio, Inc. received marketing authorization in the United Arab Emirates for ANKTIVA across BCG-unresponsive non-muscle invasive bladder cancer and metastatic non-small cell lung cancer, while reporting second-quarter 2026 revenue of US$51.24 million and a net loss of US$230.38 million. The …

Lyell Immunopharma reports Q2 2026 net loss $44.8M, cash $228.0M; clinical milestones advance

Lyell Immunopharma reported a GAAP net loss of $44.8 million for Q2 2026 and held $228.0 million in cash, expecting this to last into Q3 2027. The company announced advancing clinical milestones for its ronde-cel and LYL273 programs, including ongoing trials and upcoming data …

Immunocore Holdings plc 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:IMCR) 2026-08-07

This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

This article highlights three companies that received new "Buy" ratings from Wall Street analysts. Lyell Immunopharma Inc., Immuneering Corp., and Atrium Therapeutics Inc. were initiated with bullish coverage, each receiving a price target significantly above their recent closing prices.

Immunocore reports second quarter financial results and provides a business update

Immunocore Holdings plc announced strong financial results for the second quarter and first half of 2026, driven by KIMMTRAK sales. The company reported $115.9 million in Q2 net revenues for KIMMTRAK, an 18% year-over-year increase, and highlighted positive five-year overall survival data for the …

Immunome (NASDAQ:IMNM) Insider Sells $2,273,555.44 in Stock

Immunome (NASDAQ:IMNM) insider Kinney Horn sold 90,616 shares of the company's stock for approximately $2.27 million on August 4th, reducing their direct ownership by 64.27%. The sale was executed under a pre-arranged Rule 10b5-1 trading plan. The clinical-stage biotechnology company, which focuses on antibody-based …

How First-Half Profitability Amid a Q2 Loss at Immunocore (IMCR) Has Changed Its Investment Story

Immunocore Holdings plc reported a significant Q2 2026 revenue increase to US$115.93 million and a narrower net loss, while the first half of 2026 saw US$222.60 million in revenue and US$12.16 million in net income, marking a shift to profitability compared to the prior …

ImmunityBio (IBRX) group led by Soon-Shiong holds 64.8% stake

ImmunityBio, Inc. (IBRX) is majority-controlled by Patrick Soon-Shiong and affiliated entities, who beneficially own 64.8% of the common stock, totaling 745,518,285 shares. This ownership is distributed among several entities, including Cambridge Equities, Nant Capital, California Capital Equity, and NantWorks. The report is based on …

Immunocore outlines TEBE-AM data as early as end of 2026 while scaling KIMMTRAK beyond ~1,000 patients per year

Earnings Call Insights: Immunocore Holdings plc (IMCR) Q2 2026 MANAGEMENT VIEW * Dr. Bahija Jallal (CEO & Executive Director) emphasized execution against three priorities: "maximizing the value of KIMMTRAK, advancing our melanoma portfolio and expanding into other tumor types and realizing opportunities in infection …

IMNM (IMNM) investor ABHMC II LLC plans sale of 108,504 common shares

ABHMC II LLC, an investor in Immunome Inc. (IMNM), plans to sell 108,504 common shares via Merrill Lynch on or after August 6, 2026. These shares, valued at approximately $2.77 million, were acquired through a private placement on October 3, 2023. The filing also …

Immunovant, Inc. Q1 2027 Earnings Call Summary

Immunovant, Inc. Q1 2027 Earnings Call Summary - Moby Strategic Execution and Pipeline Acceleration Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. …

Lyell Immunopharma: Q2 Earnings Snapshot

Calf-health company ImmuCell schedules Aug. 14 results webcast

ImmuCell (Nasdaq: ICCC) will report its unaudited financial results for the quarter ended June 30, 2026, after market close on August 13, 2026. The company will host a conference call and webcast on August 14, 2026, at 9:00 AM ET to discuss these results, …

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2026

ImmuCell Corporation will announce its unaudited financial results for the quarter ended June 30, 2026, after market close on Thursday, August 13, 2026. The company will host a conference call and webcast on August 14, 2026, at 9:00 AM ET to discuss these results. …

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome, Inc. announced that its Compensation Committee granted inducement awards of non-statutory stock options to nine new employees on August 3, 2026. These options allow them to purchase an aggregate of 176,500 shares of common stock at an exercise price of $23.01 per share. …

Immunovant Q1 Earnings Call Highlights

Lyell Immunopharma (NASDAQ:LYEL) Earns Buy Rating from Analysts at Stifel Nicolaus

Stifel Nicolaus initiated coverage on Lyell Immunopharma (NASDAQ:LYEL) with a "buy" rating and a $36.00 price target, suggesting a significant upside. This comes amidst generally favorable analyst sentiment, with an average "Moderate Buy" rating and a $42.00 target price from other firms. Lyell Immunopharma, …

Immunovant, Inc. Q1 2027: Net loss $153.2M, EPS $(0.75) — 10-Q Summary

Immunovant, Inc. reported a net loss of $153.2 million for Q1 2027, an increase from $120.6 million in the prior year, with diluted loss per share at $(0.75). The company generated no revenues for the quarter and is focusing on the development of IMVT-1402 …

Immunocore Holdings PLC (IMCR) (Q2 2026) Earnings Call Highlights: Strong Kimtrak Growth and ...

Immunocore Holdings PLC reported strong Q2 2026 earnings, with Kimtrak generating $223 million in net revenue in the first half of 2026, marking a 16% year-over-year growth. The company presented positive five-year overall survival data for Kimtrak in uveal melanoma and is advancing three …

Immunovant, Inc. Stock 12‑Month Price Target Raised to $47.56, Implies 21% Upside

Immunovant, Inc.'s stock price target has been increased to $47.56 from $47.06 by 16 analysts, implying a 21% potential upside based on its Aug. 5 closing price. The consensus rating remains "Buy," with 12 analysts recommending Buy and 4 recommending Hold.

Immunocore Q2 2026 slides: KIMMTRAK doubles 5-year survival rates

Immunocore Holdings reported its Q2 2026 financial results, highlighting that its therapy KIMMTRAK doubled the five-year survival rates in metastatic uveal melanoma patients. The company reported $115.9 million in revenue, an 18% year-over-year growth, and narrowed its net loss significantly. Immunocore is expanding its …

Immunovant's Q1 Loss Wider Than Expected, Pipeline in Progress

Immunovant (IMVT) reported a wider-than-expected net loss of 75 cents per share in Q1 fiscal 2027, surpassing the Zacks Consensus Estimate of a 66-cent loss. Despite no approved products, the company is advancing its lead asset, IMVT-1402, an FcRn inhibitor, through multiple clinical trials …

FMR LLC (IMCR) discloses 4.3M Immunocore shares under amended 13G

FMR LLC and Abigail P. Johnson have reported their beneficial ownership of Immunocore Holdings plc (IMCR) common stock via an amended Schedule 13G filing. FMR LLC beneficially owns 4,307,246 shares, representing an 8.8% stake, with sole dispositive power. Abigail P. Johnson also holds sole …

AC Immune (NasdaqGM:ACIU) Stock Price Shrugs Off Surprise Quarterly Profit

AC Immune (NasdaqGM:ACIU) reported a surprise Q2 2026 profit with basic earnings per share of 0.018701 CHF and revenue of 15.113m CHF, a significant turnaround from a loss in the previous year. Despite this positive financial shift for the Alzheimer and neurodegeneration specialist, the …

Immunovant reports $153.2M net loss, $797.8M cash as of June 30, 2026

Immunovant reported a net loss of $153.2 million and held $797.8 million in cash as of June 30, 2026. The company's R&D expenses increased, while G&A expenses decreased. Immunovant confirmed that the clinical development timelines for IMVT-1402 across six indications remain on track, with …

LYELL IMMUNOPHARMA, INC. : STIFEL INITIATES COVERAGE WITH BUY RATING; TARGET PRICE $36

Stifel has initiated coverage on Lyell Immunopharma, Inc. (LYEL.O) with a buy rating, setting a target price of $36. This announcement comes from Reuters and reflects an analyst's opinion on the company's prospects. The article also includes a disclaimer stating that the content is …